+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Organ and Tissue Transplantation and Alternatives

  • ID: 5230128
  • Report
  • December 2020
  • Region: Global
  • 207 Pages
  • BCC Research

FEATURED COMPANIES

  • Abbvie Inc.
  • Amgen Inc.
  • Bayer Ag
  • Caredx Inc.
  • Johnson & Johnson
  • Novartis Ag

Report Scope:

This report offers forecasts, by product segment, from 2018 through 2024, including supporting analyses for projections. Product segments covered consist of the solid organ (e.g., kidneys, liver, heart-lung, pancreas, intestines) and the tissue transplantation (e.g., bone, skin, cornea, heart valve) markets, along with the pharmaceuticals that accompany each market.

Also included are experimental xenografts and artificial organs; tissue transplants; and cell transplants (e.g., bone marrow, cord blood, peripheral blood, islet cell). The report touches on the use of fetal cells, stem cells, and altered cancer cells.

The arrangement of this report offers an overview of the key elements in the transplantation process: tissue typing, procurement and preservation, immunosuppressants for solid organ and tissue transplants, and postoperative monitoring. International markets are discussed, and information is provided on industry structure and the regulatory environment.

Within each section are discussions of commercialization opportunities for each segment of the market. New or emerging devices, techniques, and pharmaceuticals are highlighted.

Profiles of leading companies involved with solid organ transplantation, tissue transplantation, and alternative technologies are included. The report provides information on company placement within the market and strategic analyses of the companies’ available and emerging products.

An appendix featuring various terms and processes used in transplantation is provided at the end of the report.

This report cites autologous products only in relation to their impact on the market for allografts. It does not include blood products, except for peripheral and umbilical cord blood as a source of stem cells.

By geography, the market has been segmented into North America, Europe, Asia-Pacific, and Rest of the World regions. Detailed analysis of the market in major countries such as the U.S., Germany, the U.K., Italy, France, Spain, Japan, China, India, Brazil, Mexico, GCC countries, and South Africa will be covered in the regional segment. For market estimates, data will be provided for 2019 as the base year, with estimates for 2020 and forecast value for 2024.

Report Includes:

  • 26 data tables and 37 additional tables
  • An overview of the global organ and tissue transplantation and alternatives market
  • Estimation of the market size and analyses of market trends, with data from 2018 to 2019, estimates for 2020, and projection of CAGR through 2024
  • Details about organ and tissue transplantation and alternatives, their pathophysiology and effects, and major advancement and latest trends
  • A look at the regulatory scenarios and initiatives by a government organization
  • Analysis of current and future market dynamics and identification of key drivers, restraints, and opportunities such as increasing incidence of organ donations, improved awareness about organ donations, side effects of organ and tissue transplantation, and antibiotic resistance infections
  • Coverage of emerging procedures and products in development and discussion on the prevalence of major chronic diseases which initiates organ damage or donation
  • Discussion on the role of the organ procurement organization and information on transplantation process and preparation and coverage of issues like black market donors
  • Impact analysis of COVID-19 on organ and tissue transplantation and alternatives market
  • Market share analysis of the key companies of the industry and coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
  • Company profiles of major players of the industry, including Abiomed Inc., Bayer AG, F. Hoffmann-La Roche & Co., Johnson & Johnson, Novartis AG, Pfizer Inc., and XVIVO Perfusion
Note: Product cover images may vary from those shown

FEATURED COMPANIES

  • Abbvie Inc.
  • Amgen Inc.
  • Bayer Ag
  • Caredx Inc.
  • Johnson & Johnson
  • Novartis Ag

Chapter 1 Introduction

  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Geographic Breakdown
  • Analyst's Credentials
  • Custom Research
  • Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

  • Organ and Tissue Transplantation and Alternatives
  • Cost of Care
  • Solid Organ Preservation
  • Immunosuppression
  • Organ Transplantation Alternatives
  • Trends in Organ and Tissue Transplantation Techniques and Their Alternatives
  • 3D Tissue Assembly
  • Nanotechnology for Tissue Regeneration
  • Innovation by Small Firms

Chapter 4 Market Dynamics

  • Market Drivers
  • Increasing Epidemiology of Different Diseases Influencing Organ Transplantations
  • Rise in the Geriatric Population
  • Rising Awareness of Importance of Organ and Tissue Donation
  • New Therapeutic Pathways for Organ Transplantation and Their Alternatives
  • Market Restraints
  • Challenges in Human Leukocyte Antigen (HLA) Sequencing
  • Demand and Supply Gap
  • Market Opportunities
  • Growing Economic Benefits of Organ and Tissue Transplants
  • Improvement in Healthcare Infrastructure

Chapter 5 Market Breakdown by Product & Devices

  • Global Market for Organ and Tissue Transplantation and Alternatives
  • Alternative Technologies
  • Market Size and Forecast
  • Alternatives to Heart Transplantation
  • Surgical
  • Mechanical
  • Total Artificial Heart
  • Ventricular Assist Devices (VADs)
  • Generations of Designs
  • Orthopedic Alternatives
  • Tissue Products
  • Market Size and Forecast
  • Immunosuppressants
  • Market Size and Forecast
  • Solid Organ Preservation Solutions
  • Market Size and Forecast
  • Preservation Solutions in Development
  • Tissue Typing
  • Market Size and Forecast

Chapter 6 Market Breakdown by Region

  • Global Market for Organ and Tissue Transplantation and Alternatives by Region
  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia and New Zealand
  • Rest of Asia-Pacific
  • Rest of the World
  • Market Analysis
  • Brazil
  • South Africa
  • Rest of the World Countries

Chapter 7 Impact of COVID-19

  • Introduction
  • Impact on Kidney Transplant Program
  • Impact on Pharmaceutical Companies
  • Donor Testing
  • COVID-19 in Transplant Recipients
  • Minimizing Infection Risk in Recipients
  • Future Perspectives

Chapter 8 Overview of Donation Process

  • Introduction
  • Black Market Donors
  • The Transplantation Process
  • Cost of Solid Organ Transplantation in the U.S.

Chapter 9 Regulations & Reimbursement

  • Regulations in the U.S.
  • U.S. Federal Regulation of Human Tissue
  • History of Regulation in the U.S.
  • Regulations Outside the U.S.
  • Reimbursement in the U.S.
  • Organ Acquisition Costs
  • Reimbursement for Hospital Costs
  • Reimbursement for Physician Services
  • Reimbursement for Immunosuppressants in the U.S.
  • Reimbursement Outside the U.S.
  • Treatment in EU Countries

Chapter 10 Competitive Landscape

  • Global Company Ranking Analysis
  • Mergers and Acquisitions
  • Agreements, Launches, Collaborations, and Partnerships

Chapter 11 Company Profiles

  • Abiomed Inc.
  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer Ag
  • Bristol-Myers Squibb
  • Caredx Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Mylan N.V.
  • Novartis Ag
  • Pfizer Inc.
  • Transmedics Inc.
  • Vertex Pharmaceuticals Inc.
  • Xvivo Perfusion

Chapter 12 Appendix: Acronyms

List of Tables
Summary Table A: Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Summary Table B: Global Market for Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 1: MiMedx: Patent Portfolio
Table 2: Product Launches in Transplant Diagnostics, 2012-2016
Table 3: Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Table 4: Global Market for Alternative Technologies in Organ and Tissue Transplantation and Alternatives, Through 2024
Table 5: Selected Global Commercial Opportunities for New Orthopedic Devices in the Future
Table 6: Indications for Bioartificial Liver Transplantation
Table 7: Global Market for Alternative Technologies in the Organ and Tissue Transplantation and Alternatives Market, by Region, Through 2024
Table 8: Global Market for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, Through 2024
Table 9: Cartilage and Soft Tissue Biologics and Biomaterials
Table 10: Global Market of Tissue Products in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 11: Therapeutic Effects of Immunosuppressants
Table 12: Global Market for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives Market, Through 2024
Table 13: Immunosuppressants, by Drug Class, Generic Name, Brand Name, and Manufacturer
Table 14: Global Market of Immunosuppressants in the Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 15: Cold Ischemia Time for Transplanted Organs
Table 16: Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, Through 2024
Table 17: Optimal Preservation Solution Design
Table 18: Major Organ Preservation Solutions
Table 19: Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 20: Tissue Typing Technologies
Table 21: Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, Through 2024
Table 22: Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 23: Global Market for Organ and Tissue Transplantation and Alternatives, by Region, Through 2024
Table 24: North American Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Table 25: North American Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
Table 26: European Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Table 27: European Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
Table 28: Transplant Numbers in Germany, 2013-2019
Table 29: Statistics for Cost of Bone Damage Repair and Related Disorders in Europe
Table 30: Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Table 31: Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
Table 32: Types of Organ Rejection After Transplant Procedures
Table 33: Organ Transplantation Rates in Southeast Asian Countries, 2011-2014
Table 34: Rest of the World Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, Through 2024
Table 35: Registered Liver Transplantations (LT)/Kidney Transplantation in Middle East Countries, 2017
Table 36: Rest of the World Market for Organ and Tissue Transplantation and Alternatives, by Country, Through 2024
Table 37: Communicable and Noncommunicable Diseases Leading to Mortality in Brazil, 2018
Table 38: Number of Organ Transplant Procedures in Brazil, by Type of Organ, 2015
Table 39: Number of Organ Transplant Procedures in Turkey, by Type of Organ, 2019-2020
Table 40: Pharmaceutical Company Efforts to Tackle COVID-19
Table 41: U.S. Organ/Tissue Transplants: Total Estimated Transplants and Estimated Billed Charges, 2019
Table 42: Immunosuppressive Drugs Currently Covered, by Medicare*
Table 43: Overview of Medicare Immunosuppressive Drug Coverage
Table 44: Selected Transplant Industry Acquisitions, 2010-Early 2015
Table 45: Abiomed Inc: Product Portfolio
Table 46: AbbVie: Product Portfolio
Table 47: Amgen Inc.: Product Portfolio
Table 48: AstraZeneca: Product Portfolio
Table 49: Bayer AG: Product Portfolio
Table 50: Bristol-Myers Squibb: Product Portfolio
Table 51: CareDx Inc.: Product Portfolio
Table 52: F. Hoffmann-La Roche & Co.: Product Portfolio
Table 53: Johnson & Johnson: Immunosuppressants Product Portfolio
Table 54: Mylan N.V.: Product Portfolio
Table 55: Novartis AG: Product Portfolio
Table 56: Pfizer Inc.: Product Portfolio
Table 57: Pfizer Inc.: Pipeline Product Portfolio
Table 58: Transmedics Inc.: Product Portfolio
Table 59: Vertex Pharmaceuticals Inc.: Product Portfolio
Table 60: XVIVO Perfusion: Product Portfolio
Table 61: Acronyms Used in This Report

List of Figures
Summary Figure A: Global Market for Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2018-2024
Summary Figure B: Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
Summary Figure C: Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
Summary Figure D: Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
Summary Figure E: Global Market Shares for Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
Figure 1: Nanotechnology and Tissue Regeneration
Figure 2: Number of Elderly (≥ 65 Years) Receiving Kidney Transplantation in the U.S., 2014-2018
Figure 3: Number of Diabetes Patients Globally (20 to 79 Years of Age), 2000-2045
Figure 4: Waiting List for Organs in the U.S., by Type of Organ, September 2020
Figure 5: Number of Kidney Transplants, by Country, 2015
Figure 6: Patients on Waiting List vs. Transplant Performed in the U.S., by Organ, 2019
Figure 7: Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
Figure 8: Global Market for Alternative Technologies in Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 9: Global Market Shares of Alternative Technologies in Organ and Tissue Transplantation and Alternatives, 2019
Figure 10: Global Market Shares of Orthopedic Alternatives in Organ and Tissue Transplantation and Alternatives, 2019
Figure 11: Global Market for Alternative Technologies in the Organ and Tissue Transplantation and Alternatives Market, by Region, 2018-2024
Figure 12: Global Market for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, 2018-2024
Figure 13: Global Market Shares for Tissue Products in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 14: Global Market Shares for Peripheral Blood Stem Cells, Cord Blood, Bone Marrow in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 15: Global Market Shares for Orthobiologics (Bone Allografts, Machined Bone, DBM) in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 16: Global Market of Tissue Products in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
Figure 17: Global Market for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 18: Global Market Shares for Immunosuppressants in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 19: Global Market Shares for Calcineurin Inhibitors in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 20: Global Market Shares for Anti-proliferative Agents in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 21: Global Market Shares for m-TOR Inhibitors in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 22: Global Market Shares for Polyclonal Antibodies in the Organ and Tissue Transplantation and Alternatives Market, 2019
Figure 23: Global Market of Immunosuppressants in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
Figure 24: Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 25: Global Market Shares for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, 2019
Figure 26: Global Market for Solid Organ Preservation Solutions in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
Figure 27: Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 28: Global Market for Tissue Typing in Organ and Tissue Transplantation and Alternatives, by Region, 2018-2024
Figure 29: Global Market Shares of Organ and Tissue Transplantation and Alternatives, by Region, 2019
Figure 30: North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
Figure 31: North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Devices, 2019
Figure 32: North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
Figure 33: North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
Figure 34: North American Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
Figure 35: North American Market Shares for Organ and Tissue Transplantation and Alternatives, by Country, 2019
Figure 36: United States Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 37: Canadian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 38: Mexican Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 39: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
Figure 40: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
Figure 41: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
Figure 42: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
Figure 43: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
Figure 44: European Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
Figure 45: German Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 46: French Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 47: U.K. Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 48: Italian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 49: Spanish Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 50: Rest of Europe Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 51: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Product & Devices, 2019
Figure 52: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
Figure 53: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
Figure 54: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
Figure 55: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
Figure 56: Asia-Pacific Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
Figure 57: Japanese Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 58: Chinese Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 59: Indian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 60: Australia and New Zealand’s Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 61: Number of Organ Donations in Australia, by Type of Donor, 2015
Figure 62: Rest of Asia-Pacific Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 63: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Products & Devices, 2019
Figure 64: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Alternative Technologies, 2019
Figure 65: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Tissue Products, 2019
Figure 66: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Immunosuppressants, 2019
Figure 67: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Solid Organ Preservation Solutions, 2019
Figure 68: Rest of the World Market Shares of Organ and Tissue Transplantation and Alternatives, by Country, 2019
Figure 69: Brazilian Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 70: South African Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 71: Rest of the World Countries Market for Organ and Tissue Transplantation and Alternatives, 2018-2024
Figure 72: Steep Reduction in Organ Transplantation Seen During COVID-19
Figure 73: Global Market Ranking in the Organ and Tissue Transplantation and Alternatives Market, by Pharmaceutical Company, 2019
Figure 74: Global Market Ranking of Organ and Tissue Transplantation and Alternatives, by Diagnostic and Alternatives in the Organ Manufacturing Industry, 2019
Figure 75: Abiomed Inc.: Annual Revenue, 2016-2020
Figure 76: Abiomed Inc.: Revenue Shares for R&D, by Impella Devices, 2016-2020
Figure 77: AbbVie: Annual Revenue, 2016-2019
Figure 78: AbbVie: Revenue Shares, by Region/Country, 2019
Figure 79: AbbVie: Revenue Shares, by Business Unit, 2019
Figure 80: Amgen Inc.: Annual Revenue, 2016-2019
Figure 81: Amgen Inc.: Revenue Shares, by Region/Country, 2019
Figure 82: Amgen Inc.: Revenue Shares, by Products, 2019
Figure 83: AstraZeneca: Annual Revenue, 2016-2019
Figure 84: AstraZeneca: Revenue Shares, by Region/Country, 2019
Figure 85: AstraZeneca: Revenue Shares, by Business Unit, 2019
Figure 86: Bayer AG: Annual Revenue, 2016-2019
Figure 87: Bayer AG: Revenue Shares, by Region, 2019
Figure 88: Bayer AG: Revenue Shares, by Business Unit, 2019
Figure 89: Bristol-Myers Squibb: Annual Revenue, 2016-2019
Figure 90: Bristol-Myers Squibb: Revenue Shares, by Region/Country, 2019
Figure 91: Bristol-Myers Squibb: Revenue Shares, by Brands, 2019
Figure 92: CareDx Inc.: Annual Revenue, 2016-2019
Figure 93: CareDx Inc.: Revenue Shares in Pharmaceutical Segment, by Region/Country, 2019
Figure 94: CareDx Inc.: Revenue Shares, by Business Segment, 2019
Figure 95: F. Hoffmann-La Roche & Co.: Annual Revenue, 2016-2019
Figure 96: F. Hoffmann-La Roche & Co.: Revenue Shares in Pharmaceutical Segment, by Region/Country, 2019
Figure 97: F. Hoffmann-La Roche & Co.: Revenue Shares, by Business Segment, 2019
Figure 98: Johnson & Johnson: Annual Revenue, 2016-2019
Figure 99: Johnson & Johnson: Revenue Shares, by Region/Country, 2019
Figure 100: Johnson & Johnson: Revenue Shares, by Business Unit, 2019
Figure 101: Mylan N.V.: Annual Revenue, 2016-2019
Figure 102: Mylan N.V.: Revenue Shares, by Region, 2019
Figure 103: Mylan N.V.: Revenue Shares, by Business Unit, 2019
Figure 104: Novartis AG.: Annual Revenue, 2015-2019
Figure 105: Novartis AG: Revenue Shares, by Region/Country, 2019
Figure 106: Novartis AG: Revenue Shares, by Business Segment, 2019
Figure 107: Pfizer Inc.: Annual Revenue, 2016-2019
Figure 108: Pfizer Inc.: Revenue Shares, by Region/Country, 2019
Figure 109: Pfizer Inc.: Revenue Shares, by Business Segment, 2019
Figure 110: Transmedics Inc.: Annual Revenue, 2018 and 2019
Figure 111: Transmedics Inc.: Revenue Shares, by OCS Product, 2019
Figure 112: Transmedics Inc.: Revenue Shares, by Region/Country, 2019
Figure 113: Vertex Pharmaceuticals Inc.: Annual Revenue, 2016-2019
Figure 114: Vertex Pharmaceuticals Inc.: Research and Development Expense, 2017-2019
Figure 115: Vertex Pharmaceuticals Inc.: Revenue Shares, by Business Segment, 2019
Figure 116: XVIVO Perfusion: Annual Revenue, 2018 and 2019
Figure 117: XVIVO Perfusion: Revenue Shares, by Region, 2019

Note: Product cover images may vary from those shown

Loading
LOADING...

FEATURED COMPANIES

  • Abbvie Inc.
  • Amgen Inc.
  • Bayer Ag
  • Caredx Inc.
  • Johnson & Johnson
  • Novartis Ag

Growth of the global market is attributed to factors such as the growing prevalence of obesity, diabetes, cancer, and other chronic diseases which leads to organ damage, a strong product regulatory scenario, and strong investment in research and development activities by key market players including Abbott Laboratories, Cryolife Inc., Bristol-Myers Squibb, Novartis Ag, F. Hoffmann-La Roche Ltd., Medtronic, Arthrex Inc., Depuy Synthes (Johnson & Johnson), and Allosource.

Although various factors facilitate the global market for organ and tissue transplantation and alternatives, certain parameters such as challenges in HLA sequencing and gaps in supply and demand can constrain market growth. For instance, although there is an increasing need for organ transplants, the shortage of organs worldwide limits the number of transplant procedures performed, and in turn, creates an impact on transplant diagnostics procedures. An increasing number of candidates on the waiting list for organ transplant procedures worldwide further widens this gap of availability and requirement of organs for transplant purposes.

Successful organ and tissue transplantation began to arrive in the mid-1970s when tissue typing coupled with the use of cyclosporine provided more successful graft and patient survival. Today, patient and graft survival for kidney transplants is higher than 90% for the first year post-transplant, and often the success rate is 80% to 90% for five years post-transplant, with some recipients living more than 20 years after their transplant.

Continuing developments in organ procurement, organ preservation, tissue typing, and immunosuppressant use have bolstered successful transplantation surgical techniques. Evolving posttransplant drug and testing regimens have added to the success rate with close post-transplant monitoring and immunosuppressant dosage review.

Note: Product cover images may vary from those shown
  • Abiomed Inc.
  • Abbvie Inc.
  • Amgen Inc.
  • Astrazeneca
  • Bayer Ag
  • Bristol-Myers Squibb
  • Caredx Inc.
  • F. Hoffmann-La Roche Ltd.
  • Johnson & Johnson
  • Mylan N.V.
  • Novartis Ag
  • Pfizer Inc.
  • Transmedics Inc.
  • Vertex Pharmaceuticals Inc.
  • Xvivo Perfusion
Note: Product cover images may vary from those shown
Adroll
adroll